Mast cells may be activated through Tolllike receptors (TLRs) for the dose-and time-dependent release of eicosanoids. However, the signaling mechanisms of TLR-dependent rapid eicosanoid generation are not known. We previously reported a role for group V secretory phospholipase A 2 (PLA 2 ) in regulating phagocytosis of zymosan and the ensuing eicosanoid generation in mouse resident peritoneal macrophages, suggesting a role for the enzyme in innate immunity. In the present study, we have used gene knockout mice to define an essential role for MyD88 and cytosolic PLA 2 ␣ in TLR2-dependent eicosanoid generation. Furthermore, in mast cells lacking group V secretory PLA 2 , the time course of phosphorylation of ERK1/2 and of cPLA 2 ␣ was markedly truncated, leading to attenuation of eicosanoid generation in response to stimulation through TLR2, but not through c-kit or Fc⑀RI. These findings provide the first dissection of the mechanisms of TLR-dependent rapid eicosanoid generation, which is MyD88-dependent, requires cPLA 2 ␣, and is amplified by group V sPLA 2 through its regulation of the sequential phosphorylation and activation of ERK1/2 and cPLA 2 ␣. 
Introduction
Mast cells, in addition to their role as central effector cells of allergic disease and various autoimmune and inflammatory processes, are important sensors of invading pathogens. 1, 2 The latter function is mediated through pattern recognition receptors that include CD48 3 and the Toll-like receptors. [4] [5] [6] Engagement of TLRs on human and mouse mast cells leads to robust generation of cytokines and chemokines. [4] [5] [6] [7] [8] [9] [10] [11] However, there are limited data on the generation of eicosanoids by mast cells in response to TLR signaling, and there has been no dissection of its mechanism.
Eicosanoids are generated from the polyunsaturated fatty acid, arachidonic acid, which is released from the sn-2 position of cell membrane phospholipids by one of the isoforms of phospholipase A 2 (PLA 2 ). There are 4 main classes of PLA 2 , group IV cytosolic PLA 2 (cPLA 2 ), secretory PLA 2 (sPLA 2 ), group VI calciumindependent PLA 2 (iPLA 2 ), and the acetyl hydrolases of platelet activating factor (groups VII and VIII). 12 Mice in which the gene for cPLA 2 ␣ was disrupted were used to demonstrate its essential function in supplying arachidonic acid for eicosanoid biosynthesis in response to a wide range of stimuli. 13, 14 This leads to attenuation of allergic pulmonary inflammation, 14 acute lung injury in response to acid aspiration, 15 cerebral infarction following ischemia/ reperfusion injury, 13 and bleomycin-induced pulmonary fibrosis, 16 as well as difficulties with fertilization and parturition. 14 The role of sPLA 2 enzymes in eicosanoid generation has been inferred from transfection studies in which sPLA 2 enzymes have been overexpressed and from studies using inhibitors of poor specificity. However, the natural role of the endogenous sPLA 2 enzymes has remained unclear. To explore the role of endogenous group V sPLA 2 , we generated mice in which the gene was disrupted by homologous recombination. We previously reported that group V sPLA 2 regulates the phagocytosis of the yeast cell particle, zymosan, 17 and amplifies zymosan-induced eicosanoid generation from mouse resident peritoneal macrophages, 18 suggesting a role for this enzyme in innate immune responses.
We now demonstrate that TLR2-dependent LTC 4 and PGD 2 generation is attenuated in bone marrow-derived mast cells (BMMCs) lacking group V sPLA 2 , further supporting a role for this enzyme in innate immunity. We show that TLR2-dependent eicosanoid generation by mouse BMMCs requires cPLA 2 ␣ and that this is a MyD88-dependent process. Group V sPLA 2 amplifies the essential function of cPLA 2 ␣ by regulating ERK-dependent cPLA 2 ␣ phosphorylation in response to TLR2 stimulation.
Materials and methods

Materials
The study was approved by the Dana-Farber Animal Care and Use Committee (protocol no. 01-053, Group V Phospholipase A2 and Pulmonary Inflammation).
The following reagents were purchased: the synthetic lipopeptide, Rocky Hill, NJ). Recombinant mouse IL-10 was expressed in baculovirus and its concentration was determined as described. 19 
Transgenic mice
Mice heterozygous for disruption of the gene encoding group V sPLA 2 (Pla2g5) 18 were crossed for 11 generations to a BALB/cJ background. Mating pairs of Pla2g5-null and wild-type mice were derived from the litters of N11 BALB/cJ heterozygous breeding pairs. Tlr2-null 20 and Myd88-null mice 21 were provided by Dr S. Akira (Osaka University, Osaka, Japan). A homogenous population was established by backcrossing to C57BL/6 mice for more than 10 generations. Mice with disruption of the gene encoding group IV cPLA 2 ␣ (Pla2g4a) 13 were backcrossed to BALB/cJ mice for more than 10 generations.
Culture and activation of BMMCs
Mouse bone marrow cells were cultured in 50% enriched medium (RPMI 1640 containing 100 U/mL penicillin, 100 g/mL streptomycin, 10 g/mL gentamicin, 2 mM L-glutamine, 0.1 mM nonessential amino acid, and 10% FBS)/50% WEHI-3 cell (American Type Culture Collection, Manassas, VA) conditioned medium as described. 19 After 4 weeks, more than 99% of cells were BMMCs with characteristic metachromatic mast cell granules as assessed by staining with toluidine blue.
For TLR2-dependent mediator release, BMMCs were washed and resuspended at 10 6 cells per 500 L culture medium and incubated with increasing doses of Pam 3 CSK 4 for various periods. The reaction was stopped by centrifugation of the cells at 120g for 5 minutes at 4°C, and the supernatants were retained for assay of mediator release. In selected experiments, BMMCs were cultured for 2 days in 50% WEHI-3 cellconditioned medium containing 100 ng/mL SCF and 10 U/mL IL-10 prior to activation with PGN. PGD 2 and LTC 4 were assayed in the cell-free supernatant by enzyme immunoassay (EIA) according to the manufacturer's instructions (LTC 4 ; GE Healthcare, Piscataway, NJ; PGD 2 ; Cayman Chemical, Ann Arbor, MI). Secretory granule exocytosis was determined by measuring the concentration of ␤-hexosaminidase in the supernatant and lysed cell pellets as described. 22 In selected experiments, mast cells were sensitized for 1 hour at 37°C with a 1:300 dilution of monoclonal IgE anti-TNP derived from ascites and stimulated with TNP-BSA or were stimulated with SCF as described. 23, 24 Arachidonic acid release Release of radiolabeled arachidonic acid was determined in BMMCs that had been labeled to equilibrium by incubation overnight with [ 14 
Western blotting
BMMCs (5 ϫ 10 6 cells /mL) were activated with 3 g/mL Pam 3 CSK 4 for 1 to 60 minutes and the reaction was stopped by the addition of 2 volumes of ice-cold HBSS and centrifugation at 120g for 5 minutes at 4°C. The cell pellets were analyzed for expression of specific proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) immunoblotting as described. 19 Primary antibodies were used at 1 g/mL. Bound primary antibodies were detected using goat anti-rabbit IgG conjugated to horseradish peroxidase (1:3000) (Jackson ImmunoResearch Laboratory, West Grove, PA) and enhanced chemiluminescence (Pierce, Rockford, IL). Membranes used for detection of phosphoproteins were stripped and reprobed with antibodies to the total (phosphorylated and nonphosphorylated) respective protein. The expression of each phosphoprotein was determined by densitometric analysis using ImageJ software. 25 Expression was corrected for expression of total protein by dividing the intensity of each phosphoprotein band by the intensity of the respective total protein band.
Data analysis
All data are expressed as mean Ϯ SEM and were analyzed by ANOVA for kinetic and time-course data. Statistical analysis for a single dose or time was performed using Student t test. Differences were considered statistically significant for P values of less than .05. In determining the "n" for any given experiment, each individual culture of BMMCs was from a separate mouse and each "n" provides the number of separate BMMC cultures of each genotype from which data were derived.
Results
Group V sPLA 2 amplifies the cPLA 2 ␣-dependent generation of eicosanoids by BMMCs in response to TLR2 stimulation
We have previously reported that group V sPLA 2 amplifies the cPLA 2 ␣-dependent generation of eicosanoids by resident peritoneal macrophages in response to zymosan, 18 which signals in part through TLR2. 26 To evaluate the role of group V sPLA 2 in the immediate phase of eicosanoid generation elicited in response to TLR2 signaling, we measured LTC 4 and PGD 4 generation from Pla2g5-null and wild-type BMMCs stimulated with the triacylated peptide Pam 3 CSK 4 , an agonist of the TLR1/TLR2 heterodimer. LTC 4 and PGD 2 were released in a dose-and time-dependent manner by both Pla2g5-null and wild-type BMMCs that were maximal 60 minutes after stimulation with 3 g/mL Pam 3 CSK 4 ( Figure 1 ). Neither eicosanoid was released at 60 minutes in the absence of Pam 3 CSK 4 ( Figure 1C-D) . The kinetics of eicosanoid generation appeared to be biphasic with a small initial release of LTC 4 and PGD 2 within the first 5 minutes and a second phase that began between 10 and 30 minutes and that was maximal at 60 minutes. There was no further increase in eicosanoid generation after 60 minutes (data not shown). The release of both eicosanoids was significantly attenuated in Pla2g5-null BMMCs compared with wild-type BMMCs, the attenuation being most marked at 60 minutes (P Ͻ .001 and P Ͻ .0001 for LTC 4 and PGD 2 , respectively, by ANOVA for both dose-response and kinetic analyses). 4 was not accompanied by release of the preformed granule-associated mediator, ␤-hexosaminidase (data not shown).
To directly determine the role of group V sPLA 2 in amplifying the release of arachidonic acid, we labeled BMMCs to equilibrium with [ 14 C]-labeled arachidonic acid and examined its release from Pla2g5-null and wild-type BMMCs in response to Pam 3 CSK 4 . Radiolabel was detected in the culture medium 60 minutes after stimulation. Net release was 0.31% Ϯ 0.01% and 0.16% Ϯ 0.03% in wild-type and Pla2g5-null BMMCs, respectively (n ϭ 3; P ϭ .01). To determine if cPLA 2 ␣ is essential for the immediate release of LTC 4 and PGD 2 by BMMCs in response to TLR2 stimulation, BMMCs from Pla2g4a-null and wild-type control mice were stimulated with 0.1 to 3 g/mL Pam 3 CSK 4 for 60 minutes ( Figure   2A ). LTC 4 and PGD 2 generation were undetectable in BMMCs from Pla2g4a-null mice compared with 416 Ϯ 55 pg/10 6 cells of LTC 4 and 489 Ϯ 62 pg of PGD 2 /10 6 cells, in control BMMCs stimulated with 3 g/mL Pam 3 CSK 4 (n ϭ 3; P Ͻ .001).
cPLA 2 ␣ is activated by phosphorylation at serine 505 by the mitogen-activated protein kinase (MAPK) extracellular receptorstimulated kinase (ERK). 27 We therefore examined the effect of U0126, an inhibitor of MEK, the MAPK kinase immediately upstream of ERK, on eicosanoid generation and the phosphorylation of ERK and cPLA 2 ␣. Wild-type BMMCs were incubated with U0126 for 15 minutes prior to stimulation with 3 g/mL PAM 3 CSK 4 for 30 minutes. U0126 inhibited LTC 4 and PGD 2 generation from BALB/c BMMCs in response to PAM 3 CSK 4 in a dose-dependent manner ( Figure 2B Figure 2C ) confirming the role of ERK1/2 in the activation of cPLA 2 ␣ and the ensuing eicosanoid generation in response to TLR2 stimulation.
Eicosanoid generation by BMMCs in response to PAM 3 CSK 4 requires TLR2 and MyD88
To ensure that eicosanoid generation in response to Pam 3 CSK 4 was dependent upon TLR2 and was not due to stimulation of an alternate receptor by an impurity in the preparation of the ligand, we examined eicosanoid generation by BMMCs derived from Tlr2-null mice and strain-matched C57BL/6 controls. In 3 separate experiments, LTC 4 and PGD 2 generation in response to Pam 3 CSK 4 was undetectable above background in Tlr2-null BMMCs (Ͻ 25 pg/ 10 6 cells), whereas wild-type C57BL/6 BMMCs provided 725 Ϯ 133 pg/10 6 cells of LTC 4 and 1274 Ϯ 586 pg/10 6 cells of PGD 2 (mean Ϯ SEM, n ϭ 4). Eicosanoid generation in response to PGN was also absent in Tlr2-null BMMCs (data not shown).
TLRs signal through an adaptor protein that associates with their intracellular Toll/IL-1R/resistance (TIR) domain. MyD88 is commonly used as the adaptor, and both MyD88-dependent and MyD88-independent pathways have been described. 28 We therefore examined the release of LTC 4 and PGD 2 in BMMCs derived from Myd88-null mice and strain-matched C57BL/6 controls. LTC 4 and PGD 2 generation in response to Pam 3 CSK 4 was negligible and not significantly above background in Myd88-null BMMCs compared with that in C57BL/6 BMMCs (P Ͻ .002 and P Ͻ .001, respectively; n ϭ 3, Figure 3A) .
In both Tlr2-null and Myd88-null BMMCs, there was detectable baseline phosphorylation of p42 ERK that did not increase in response to Pam 3 CSK 4 , in contrast to the time-dependent and transient increase in p42 ERK phosphorylation that was observed in wild-type C57BL/6 BMMCs ( Figure 3B) . Likewise, the timedependent sequential phosphorylation of p44 ERK and cPLA 2 ␣ that was observed in wild-type C57BL/6 BMMCs in response to Pam 3 CSK 4 was not detectable in either Tlr2-null or Myd88-null BMMCs ( Figure 3B ). Thus, TLR2 and MyD88 are essential for activation of ERK, phosphorylation of cPLA 2 ␣, and eicosanoid generation in response to Pam 3 CSK 4 stimulation of BMMCs.
Group V sPLA 2 amplifies the action of cPLA 2 by regulating ERK phosphorylation
To elucidate the mechanisms through which group V sPLA 2 regulates cPLA 2 ␣-dependent eicosanoid generation, we examined 
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For personal use only. on December 29, 2017 . by guest www.bloodjournal.org From the effect of deleting Pla2g5 on phosphorylation of cPLA 2 ␣ and its upstream MAP kinases, ERK and p38. BMMCs from Pla2g5-null and wild-type mice were incubated with 3 g/mL Pam 3 CSK 4 for up to 60 minutes, and phosphoprotein expression was examined by Western blotting (Figure 4 ). The phosphorylation of cPLA 2 ␣ in response to Pam 3 CSK 4 was detectable within 1 to 2 minutes and increased to a maximum at 10 to 30 minutes in wild-type BMMCs; residual phosphorylation was still detectable 60 minutes after stimulation. In contrast, in Pla2g5-null BMMC phosphorylation was also detectable within 1 to 2 minutes, but the further rise in phosphorylation and sustained phosphorylation after 5 minutes were markedly attenuated (n ϭ 3; P ϭ .012; Figure 4A ,B).
Phosphorylation of ERK1/2 preceded that of cPLA 2 ␣ and was apparent within 1 minute of PAM 3 CSK 4 stimulation in both wild-type and Pla2g5-null BMMCs ( Figure 4A,C-D) . This phosphorylation was sustained to 10 minutes in wild-type BMMCs and was barely detectable at 30 minutes. In contrast, ERK1/2 phosphorylation declined rapidly in Pla2g5-null BMMCs and was undetectable by 10 minutes (n ϭ 3; P ϭ .015 compared with wild-type BMMCs). There was no phosphorylation of cPLA 2 ␣ or ERK1/2 up to 60 minutes in the absence of Pam 3 CSK 4 (data not shown).
Phosphorylation of p38 MAP kinase was detectable in the absence of specific stimulation ( Figure 4A ) and increased modestly and to a similar extent in wild-type and Pla2g5-null BMMCs at 1 and 2 minutes after PAM 3 CSK 4 stimulation.
The regulation of ERK and cPLA 2 ␣ by group V sPLA 2 is specific for TLR2 signaling
We have previously reported that the immediate phase of eicosanoid generation by BALB/c BMMCs stimulated through Fc⑀RI or through c-kit is intact in Pla2g5-null BMMCs. 23 We therefore examined the phosphorylation of ERK and cPLA 2 ␣ in Pla2g5-null and wild-type BALB/c BMMCs in response to signaling through Fc⑀RI and c-kit. Pla2g5-null and wild-type BMMCs were stimulated for 10 minutes with SCF or were sensitized with IgE anti-TNP and activated for 10 minutes with TNP-BSA. There was no difference in LTC 4 generation, or PGD 2 generation, in response to IgE and antigen ( Figure 5A ) or SCF ( Figure 5B ) between Pla2g5 Ϫ/Ϫ and wild-type BMMCs, as previously reported. Phosphorylation of ERK1/2 was apparent within 1 minute of stimulation, reached a maximum at 2 to 5 minutes, and then declined ( Figure 5C-D) . The phosphorylation of cPLA 2 ␣ in response to SCF or TNP-BSA was detectable at 1 minute and increased to a maximum at 10 to 30 minutes and then declined to baseline levels by 60 minutes (Figure 5C-D) . There was no detectable difference in the kinetics or degree of phosphorylation of cPLA 2 ␣ or ERK between wild-type and Pla2g5-null BMMCs in response to stimulation with IgE and antigen ( Figure 5C ) or SCF ( Figure 5D ).
Discussion
TLRs are dimeric receptors that recognize molecular signals on pathogenic organisms (pathogen-associated molecular patterns). TLR2 dimerizes with TLR1 to recognize triacylated bacterial lipopeptides mimicked by PAM 3 CSK 4 or with TLR6 to recognize diacylated peptides such as Mycoplasma macrophage-activating lipopeptide 2 (MALP-2), PGN, and lipoteichoic acid. 28, 29 In common with the IL-1␤ and IL-18 receptors, TLRs signal through a cytoplasmic TIR domain that associates with the adaptor protein MyD88, leading to activation of downstream kinases. MyD88-independent signaling can occur through TRIF (TIR domaincontaining adaptor-inducing IFN␤) or TRAM (TRIF-related adaptor molecule). These early signaling events couple to the NFB pathway and to MAP kinases to regulate mediator release and cytokine secretion. While there is a large body of data on the mechanisms of TLR-dependent cytokine generation, there is limited information on how TLRs elicit eicosanoid production. In general, eicosanoid biosynthesis can be divided into 2 phases. In the immediate phase, exemplified by Fc⑀RI-dependent mast cell activation, leukotriene and prostaglandin release begins within minutes of cellular activation and is dependent on constitutively expressed 5-LO and COX-1, respectively. 19, [30] [31] [32] In the delayed phase, prostanoids are generated over several hours, without accompanying leukotriene biosynthesis, in a manner that requires induction of COX-2. 19, 32 LPS is well established as a potent inducer of COX-2 expression and delayed prostanoid production. 33 Use of siRNA and dominant-negative constructs established a role for both TRIF and MyD88 in cPLA 2 ␣-dependent release of arachidonic acid in the mouse RAW264.7 macrophage cell line in response to LPS. 34 LPS-induced activation of cPLA 2 ␣ was also suppressed by inhibitors of p38 or ERK. 34 While stimulation of human culture-derived mast cells with PGN elicited LTC 4 generation, 5 the mechanism has not been explored. Our data therefore provide the first insight into the mechanisms by which TLR signaling elicits the rapid generation of eicosanoids and specifically of leukotrienes.
LTC 4 and PGD 2 generation in response to TLR2 agonists was dependent on cPLA 2 ␣, which was activated by ERK ( Figure 2 ). MyD88 was required for the sequential activation of ERK and cPLA 2 ␣ (Figure 3 ), suggesting that MyD88-independent pathways are not involved. While the early phases of ERK and cPLA 2 ␣ phosphorylation were intact in Pla2g5-null BMMCs, their sequential sustained phosphorylation was attenuated (Figure 4) . Interestingly, eicosanoid generation by BMMCs in response to TLR2 stimulation was biphasic with a small early phase that peaked within 10 minutes, and a second more substantial phase that was maximal at 60 minutes (Figure 1 ). The attenuation of PGD 2 and LTC 4 generation was most marked at 60 minutes. Our data therefore indicate that group V sPLA 2 regulates the activation of cPLA 2 ␣ by sustaining the activation of ERK, which is critical for the sustained activation of cPLA 2 ␣ in response to TLR2 stimulation. The sustained phosphorylation of cPLA 2 ␣ appears responsible for the later phase of LTC 4 and PGD 2 generation, which is therefore attenuated in Pla2g5-null BMMCs.
sPLA 2 enzymes have previously been shown to stimulate the sequential activation of MAP kinase and cPLA 2 ␣ when added exogenously to mouse BMMCs 35 or the 1321N1 astocytoma cell line. 36 Transfection of mouse mesangial cells with group V sPLA 2 or group IIA sPLA 2 enhanced H 2 O 2 -stimulated MAP kinase activation and cPLA 2 ␣-dependent eicosanoid generation in an ERK-dependent manner. 37 We provide the first demonstration for a role for endogenous group V sPLA 2 in regulating the sequential activation of ERK and cPLA 2 ␣. It should be noted that we used BMMCs derived from Pla2g5-null BALB/c mice. Because the allele carrying the disruption of Pla2g5 is derived from 129 ES cells, which carry a disruption of the neighboring Pla2g2a, these mice lack both group V sPLA 2 and group IIA sPLA 2 . 17, 18 That group IIA PLA 2 is not required for the sustained phosphorylation of ERK and cPLA 2 is apparent from experiments with BMMCs derived from C57BL/6 BMMCs that also lack group For personal use only. on December 29, 2017 . by guest www.bloodjournal.org From IIA sPLA 2 38 and that were used as controls for mice deficient in TLR2, MyD88, or cPLA 2 ␣ (Figure 3 ). Ongoing studies are addressing the mechanisms through which group V sPLA 2 sustains the activation of ERK.
While exogenous sPLA 2 or sPLA 2 overexpressed by transfection in various cells is capable of amplifying the essential role of cPLA 2 ␣ in the biosynthesis of eicosanoids, [39] [40] [41] [42] [43] the role of the endogenous sPLA 2 enzymes has remained poorly defined. Using mice in which the gene encoding group V sPLA 2 was deleted, we demonstrated that this sPLA 2 amplifies the essential function of cPLA 2 ␣ in zymosan-induced LTC 4 and PGE 2 biosynthesis by resident mouse peritoneal macrophages. 18 This translated in vivo to attenuation of the early phase of zymosan-induced peritonitis. 18 We then demonstrated that group V sPLA 2 regulates phagocytosis of zymosan by resident peritoneal macrophages. 17 Others have demonstrated that group V sPLA 2 has bactericidal activity toward M luteus that is enhanced after treatment of the bacteria with lysozyme. 44, 45 These combined data suggest a role for group V sPLA 2 in innate immune responses. Our present findings strengthen the suggestion that this sPLA 2 plays a role in innate immunity, a role that is shared with group IIA sPLA 2 , which is a more potent bactericidal agent than group V sPLA 2 with a spectrum of activity that extends to Gram-negative bacteria. 44, 45 Furthermore, transgenic mice expressing human group IIA sPLA 2 are resistant to infection with Bacillus anthracis, and in vivo administration of recombinant group IIA sPLA 2 protected mice against infection with this organism. 46 Thus, a picture is emerging that sPLA 2 enzymes may have evolved and retained their diversity in mammals due their role in innate immunity.
The role of group V sPLA 2 in regulating eicosanoid generation, inflammation, and phagocytosis contrasts with the role of cPLA 2 ␣ revealed through gene disruption. Lack of cPLA 2 ␣ leads to profound deficits in the generation of leukotrienes and prostaglandins and results in the marked attenuation of inflammatory responses and also certain physiologic functions such as parturition, [13] [14] [15] [16] raising important questions as to the possible side effects of targeting cPLA 2 ␣ in human disease. In contrast, disruption of group V sPLA 2 led to modest deficits in eicosanoid generation and phagocytosis. 17, 18, 23 Thus, sPLA 2 enzymes, and group V sPLA 2 in particular, might be attractive therapeutic targets in inflammation, blunting rather than ablating the generation of lipid mediators. We have found that group V sPLA 2 regulates eicosanoid generation from mouse BMMCs in response to stimulation through TLR2 (Figure 1 ) with a limited role in regulating eicosanoid generation in response to signaling through Fc⑀RI or c-kit that is limited to a strain-dependent role in delayed phase COX-2 induction and PGD 2 generation ( Figure 5 ). 23 If this specificity extends to human cells, inhibition of group V sPLA 2 might prove a useful strategy in targeting overexuberant TLR-dependent inflammation while leaving allergic inflammatory responses substantially intact. Whether targeting sPLA 2 in humans would be accompanied by an increase in susceptibility to infection remains to be seen and will be addressed in the first instance in Pla2g5-null mice. However, it is notable that while mice lacking 5-LO display impaired phagocytosis and killing of Klebsiella pneumoniae, 47 an increased risk of opportunist infections from the use in humans of the 5-LO inhibitor zileuton has not emerged to date.
In conclusion, our data provide the first dissection of rapid eicosanoid generation in response to TLR stimulation, demonstrate a role for endogenous group V sPLA 2 in regulating the sequential activation of ERK and cPLA 2 ␣, and provide further evidence that group V sPLA 2 is a participant in innate immune responses.
